Preora Diagnostics Inc., a privately held medical technology company developing low-cost and highly accurate cancer screening tests, today announced that results from its Partial Wave Spectroscopy (PWS) Nanocytology optimization study support Preora’s intention of providing its lung cancer screening test to primary care physicians’ offices. Study data appear in the current issue of the peer-reviewed journal Biomedical Optics Express.
Following a previous proof-of-concept study, Preora Diagnostics began optimizing all aspects of its screening protocol, including buccal (cheek) cell collection, tissue storage and shipping, specimen staining and slide preparation, and specimen analysis and interpretation. The published paper references 653 specimens from human clinical patients and healthy volunteers, stating, “In conclusion, we have developed and validated a simple, robust and easy to implement standard operating procedures for buccal PWS nanocytology as well as a commercial-ready PWS instrument.”
